IL6 and ovarian carcinoma: In vitro studies using ovarian cancer cells and CAF‐conditioned media have demonstrated that CAFs reinforce Paclitaxel resistance by activating the epithelial‐to‐mesenchymal transition (EMT) through the IL‐6/Janus kinase 2 (JAK2)/STAT3 axis; these findings are further supported by clinical tissue analysis showing that elevated interstitial IL‐6 correlates with reduced chemotherapy sensitivity.24